Shaina McGrath

Ms. Shaina McGrath

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2023 in Nature
Verified
Journal Article
Closed access
PDF file
AMAnkit Malik
Ankit Malik
DSDeepika Sharma
Deepika Sharma
RARaúl Aguirre-Gamboa
Raúl Aguirre-Gamboa
SMShaina McGrath
Shaina McGrath
SZSarah Zabala
Sarah Zabala
BJBana Jabri
Bana Jabri

19 November 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
FAFerdinand Althammer
Ferdinand Althammer
RRRanjan K. Roy
Ranjan K. Roy
MKMatthew K. Kirchner
Matthew K. Kirchner
YPYuval Podpecan
Yuval Podpecan
JHJemima Helen
Jemima Helen
JSJavier E. Stern
Javier E. Stern
Activation of microglia, the resident immune cells of the central nervous system, leading to the subsequent release of pro-inflammatory cytokines, has been linked to cardiac remodeling, autonomic disbalance, and cognitive deficits in heart failure (HF). While previous studies emphasized the role of hippocampal Angiotensin II (AngII) signaling in HF-induced microglial activation, unanswered mechanistic questions persist. Evidence suggests significant interactions between microglia and local microvasculature, potentially affecting blood–brain barrier integrity and cerebral blood flow regulation. Still, whether the microglial-vascular interface is affected in the brain during HF remains unknown. Using a well-established ischemic HF rat model, we demonstrate the increased abundance of vessel-associated microglia (VAM) in HF rat hippocampi, along with an increased expression of AngII AT1a receptors. Acute AngII administration to sham rats induced microglia recruitment to brain capillaries, along with increased expression of TNFα. Conversely, administering an AT1aR blocker to HF rats prevented the recruitment of microglia to blood vessels, normalizing their levels to those in healthy rats. These results highlight the critical importance of a rather understudied phenomenon (i.e., microglia-vascular interactions in the brain) in the context of the pathophysiology of a highly prevalent cardiovascular disease, and unveil novel potential therapeutic avenues aimed at mitigating neuroinflammation in cardiovascular diseases.

23 December 2022 in Allergies
Verified
Journal Article
Open access
PDF file
RTRosalinda Monroy Del Toro
Rosalinda Monroy Del Toro
RIRyan Incrocci
Ryan Incrocci
ONOlivia Negris
Olivia Negris
SMShaina McGrath
Shaina McGrath
JSJulie Swartzendruber
Julie Swartzendruber
Probiotics are an attractive target for reducing the incidence of allergic disease. Bacillus subtilis is a gut-associated probiotic bacteria that can suppress allergic lung disease; however, it is not clear for how long this protection lasts. We exposed C57Bl/6 mice to B. subtilis via oral gavage and challenged them with intranasal house-dust mite for up to 8 weeks. We found that B. subtilis treatment was able to provide protection from eosinophil infiltration of the airways for 3 weeks. This loss of protection correlated with an increase in the eosinophil chemoattractant CCL24. Additionally, we demonstrate that B. subtilis treatment altered the bacterial composition by increasing the phylum Bacteroidetes and Verrucomicorbiota. The phylum Verrucomicorbiota was reduced in B. subtilis-treated mice at 8 weeks when protection was lost. These results support B. subtilis as a prophylactic for preventing the production of allergic lung disease and highlights that protection can last up to 3 weeks. This work also expands our understanding of how B. subtilis mediates protection and that in addition to modifying the immune system it is also altering the host microbiota.